Lisa Cabrera, MD
Nephrology · San Antonio, TXNPI 1811962723
Payments from drug & device makers
Across 497 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Fresenius USA Marketing, Inc.$1K
- OPKO Pharmaceuticals, LLC$1K
- Amgen$901
- Bayer$818
- Medtronic$568
- plus $5K from 29 others
What the payments were for
- Consulting fees$5204%
- Food & beverage$11,70595%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 85 | $2,567 |
| Fresenius USA Marketing, Inc. | 77 | $1,274 |
| OPKO Pharmaceuticals, LLC | 60 | $1,015 |
| Amgen(2 entities) | 37 | $901 |
| Bayer | 39 | $818 |
| Medtronic | 7 | $568 |
| GSK | 9 | $501 |
| Boehringer Ingelheim | 27 | $410 |
| Daiichi Sankyo Inc. | 20 | $398 |
| Lilly USA, LLC | 13 | $363 |
| Novo Nordisk | 15 | $346 |
| Otsuka America Pharmaceutical, Inc. | 12 | $334 |
| Aurinia Pharma U.S., Inc. | 6 | $319 |
| Travere Therapeutics, Inc. | 17 | $299 |
| Calliditas Therapeutics US Inc. | 12 | $284 |
| Fresenius USA Inc. | 1 | $250 |
| Ardelyx, Inc. | 9 | $219 |
| Vifor Pharma, Inc. | 10 | $204 |
| Akebia Therapeutics Inc | 4 | $163 |
| Venturemed Group, Inc. | 1 | $153 |
| Nxstage Medical, Inc. | 2 | $151 |
| Mallinckrodt Hospital Products Inc. | 2 | $142 |
| Novartis | 5 | $110 |
| ANI Pharmaceuticals, Inc. | 6 | $105 |
| Merck | 5 | $79 |
| Kyowa Kirin, Inc. | 3 | $67 |
| AbbVie | 2 | $41 |
| Cormedix Inc. | 2 | $41 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Tactile Systems Technology Inc | 2 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$763
- LOKELMA$518
- BENLYSTA$395
- ELLIPSYS VASCULAR ACCESS SYSTEM$264
- LUPKYNIS$210
- Rayaldee$180
- FLEX Vessel Prep System$153
- Abre$132
- JYNARQUE$127
- JARDIANCE$125
- Kerendia$125
- KRYSTEXXA$125
- NXSTAGE SYSTEM ONE$124
- ACTHAR$117
- Tavneos$117
How this compares
$12,278 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 1,153 | $896,074 |
| VelphoroSucroferric Oxyhydroxide | 244 | $836,695 |
| JardianceEmpagliflozin | 449 | $446,219 |
| OzempicSemaglutide | 422 | $442,697 |
| KerendiaFinerenone | 328 | $323,299 |
| MounjaroTirzepatide | 202 | $225,331 |
| RybelsusSemaglutide | 149 | $222,632 |
| LokelmaSodium Zirconium Cyclosilicate | 215 | $172,852 |
| XphozahTenapanor Hcl | 37 | $113,221 |
| VeltassaPatiromer Calcium Sorbitex | 88 | $84,695 |
| TrulicityDulaglutide | 61 | $80,873 |
| RayaldeeCalcifediol | 55 | $80,718 |
| AuryxiaFerric Citrate | 36 | $75,834 |
| Bydureon BciseExenatide Microspheres | 38 | $63,140 |
| JanuviaSitagliptin Phosphate | 30 | $33,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $2,567 | $1,068,9261,368 claims |
| Fresenius USA Marketing, Inc.Velphoro | $1,274 | $836,695244 claims |
| Novo NordiskOzempic, Rybelsus | $346 | $665,329571 claims |
| Boehringer IngelheimJardiance | $410 | $446,219449 claims |
| BayerKerendia | $818 | $323,299328 claims |
| Lilly USA, LLCMounjaro, Trulicity | $363 | $306,203263 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,015 | $80,71855 claims |
| Akebia Therapeutics IncAuryxia | $163 | $75,83436 claims |
| MerckJanuvia | $79 | $33,05530 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $105 | $78139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.
Other nephrology in San Antonio
- Pablo PergolaSan Antonio$14.2M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Wesley CalhounSan Antonio$3.5M
- Shweta BansalSan Antonio$1.7M
- Robert SzewcSan Antonio$1.5M
- Rashid SharafSan Antonio$661K
- Varshasb BroumandSan Antonio$538K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.